CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer

Nervous system relapse of patients with advanced HER2–neu-positive breast cancer is an increasing problem, with one-third of women developing brain metastases. Standard therapies using steroids, surgery and radiotherapy do not provide a lasting response. We evaluated CPT-11 and bevacizumab, which ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Sengupta, S., Rojas, R., Mahadevan, A., Kasper, E., Jeyapalan, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664841/
https://www.ncbi.nlm.nih.gov/pubmed/26634139
http://dx.doi.org/10.1093/omcr/omv010
_version_ 1782403499912331264
author Sengupta, S.
Rojas, R.
Mahadevan, A.
Kasper, E.
Jeyapalan, S.
author_facet Sengupta, S.
Rojas, R.
Mahadevan, A.
Kasper, E.
Jeyapalan, S.
author_sort Sengupta, S.
collection PubMed
description Nervous system relapse of patients with advanced HER2–neu-positive breast cancer is an increasing problem, with one-third of women developing brain metastases. Standard therapies using steroids, surgery and radiotherapy do not provide a lasting response. We evaluated CPT-11 and bevacizumab, which can both cross the blood–brain barrier, as combination therapy to treat HER2–neu-positive breast cancer with brain metastases.
format Online
Article
Text
id pubmed-4664841
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-46648412015-12-02 CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer Sengupta, S. Rojas, R. Mahadevan, A. Kasper, E. Jeyapalan, S. Oxf Med Case Reports Case Reports Nervous system relapse of patients with advanced HER2–neu-positive breast cancer is an increasing problem, with one-third of women developing brain metastases. Standard therapies using steroids, surgery and radiotherapy do not provide a lasting response. We evaluated CPT-11 and bevacizumab, which can both cross the blood–brain barrier, as combination therapy to treat HER2–neu-positive breast cancer with brain metastases. Oxford University Press 2015-04-10 /pmc/articles/PMC4664841/ /pubmed/26634139 http://dx.doi.org/10.1093/omcr/omv010 Text en © The Author 2015. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Case Reports
Sengupta, S.
Rojas, R.
Mahadevan, A.
Kasper, E.
Jeyapalan, S.
CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer
title CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer
title_full CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer
title_fullStr CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer
title_full_unstemmed CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer
title_short CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer
title_sort cpt-11/bevacizumab for the treatment of refractory brain metastases in patients with her2–neu-positive breast cancer
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664841/
https://www.ncbi.nlm.nih.gov/pubmed/26634139
http://dx.doi.org/10.1093/omcr/omv010
work_keys_str_mv AT senguptas cpt11bevacizumabforthetreatmentofrefractorybrainmetastasesinpatientswithher2neupositivebreastcancer
AT rojasr cpt11bevacizumabforthetreatmentofrefractorybrainmetastasesinpatientswithher2neupositivebreastcancer
AT mahadevana cpt11bevacizumabforthetreatmentofrefractorybrainmetastasesinpatientswithher2neupositivebreastcancer
AT kaspere cpt11bevacizumabforthetreatmentofrefractorybrainmetastasesinpatientswithher2neupositivebreastcancer
AT jeyapalans cpt11bevacizumabforthetreatmentofrefractorybrainmetastasesinpatientswithher2neupositivebreastcancer

Ejemplares similares